Previous 10 | Next 10 |
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary smal...
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...
FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson’s good safety profile There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in children Can-Fite BioPharma Ltd . (NYSE A...
Study will aim to enroll about 20 patients to establish safety and clinical activity Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, tod...
2023-11-30 07:08:39 ET More on Can-Fite Biopharma Can-Fite climbs on mid-stage data for liver cancer therapy Can-Fite Biopharma discloses $100M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Can-Fite Biopharma Historical earnings data fo...
Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...
2023-11-22 09:57:58 ET DENVER, Colo., Nov. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ESGL Holdings Ltd (NASDAQ: ESGL), SciSparc Ltd (NASDAQ: SPRC), Safety Shot Inc (NASDAQ: SHOT), PaxMedica Inc ...
PETACH TIKVA, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive...
2023-11-21 13:19:04 ET More on Can-Fite Biopharma Can-Fite Biopharma discloses $100M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Can-Fite Biopharma Historical earnings data for Can-Fite Biopharma Financial information for Can-Fite Bio...
2023-11-21 13:10:50 ET DENVER, Colo., Nov. 20, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; ProKidney Corp (NASDAQ: PROK), Can Fite Biofarma Ltd (AMEX: CANF), Seres Therapeutics Inc (NASDAQ: MCR...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled ...
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...